Celgene Thalomid Initial Availability Will Be Limited to 500 Physicians
Executive Summary
Celgene's Thalomid STEPS program will limit availability to 500 physicians and 500 pharmacies during the first three months of marketing.
You may also be interested in...
US FDA’s Most Controversial Drug Approval Decisions, From A To Z
Following accelerated approval of Biogen’s Alzheimer’s drug aducanumab in the US, we look back at 10 of the FDA’s most controversial drug approval decisions, from Addyi to Zohydro.
US FDA’s Most Controversial Drug Approval Decisions, From A To Z
With action imminent on Biogen’s Alzheimer’s drug aducanumab, the Pink Sheet looks back at 10 of FDA’s most controversial drug approval decisions, from Addyi to Zohydro.
Restricted Distribution Should Be Limited To Drugs With Unique Benefit – FDA
Risk management plans that include restricted distribution components should be limited to products that offer a unique benefit in a specific group of patients, according to FDA